Evaluating Nulojix Long-Term Safety in Transplant.

Trial Profile

Evaluating Nulojix Long-Term Safety in Transplant.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 May 2017

At a glance

  • Drugs Belatacept (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms ENLiST
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 09 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Feb 2016 Planned number of patients changed from 3500 to 1130, according to ClinicalTrials.gov record.
    • 12 Feb 2016 Planned End Date changed from 1 Jan 2017 to 1 Apr 2019, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top